Gossamer Bio extended the early tender deadline for its exchange offer of 5.00% convertible notes due 2027 for new 7.50% convertible notes, equity securities, and warrants. As of June 1, $181.052 million of the existing notes had been tendered, approaching the 98% minimum threshold required for the transaction to close.